吉西他滨
医学
内科学
临床终点
三阴性乳腺癌
紫杉醇
肿瘤科
乳腺癌
顺铂
临床研究阶段
化疗
不利影响
转移性乳腺癌
癌症
随机对照试验
作者
Biyun Wang,Tao Sun,Yannan Zhao,Shusen Wang,Jian Zhang,Zhonghua Wang,Yuee Teng,Li Cai,Min Yan,Xiaojia Wang,Zefei Jiang,Yueyin Pan,Jianfeng Luo,Zhimin Shao,Jiong Wu,Xiaomao Guo,Xichun Hu
标识
DOI:10.1038/s41467-022-31704-7
摘要
Abstract Platinum is recommended in combination with gemcitabine in the treatment of metastatic triple-negative breast cancer (mTNBC). We conduct a randomized phase 3, controlled, open-label trial to compare nab-paclitaxel/cisplatin (AP) with gemcitabine/cisplatin (GP) in mTNBC patients (ClinicalTrials.gov NCT02546934). 254 patients with untreated mTNBC randomly receive AP (nab-paclitaxel 125 mg/m² on day 1, 8 and cisplatin 75 mg/m² on day 1) or GP (gemcitabine 1250 mg/m² on day 1, 8 and cisplatin 75 mg/m² on day 1) intravenously every 3 weeks until progression disease, intolerable toxicity or withdrawal of consent. The primary endpoint is progression-free survival (PFS); secondary endpoints are objective response rate (ORR), safety and overall survival (OS). The trial has met pre-specified endpoints. The median PFS is 9.8 months with AP as compared to 7.4 months with GP (stratified HR, 0.67; 95% CI, 0.50–0.88; P = 0.004). AP significantly increases ORR (81.1% vs . 56.3%, P < 0.001) and prolongs OS (stratified HR, 0.62; 95% CI, 0.44–0.90; P = 0.010) to GP. Of grade 3 or 4 adverse events, a significantly higher incidence of neuropathy in AP and thrombocytopenia in GP is noted. These findings warrant further assessment of adding novel agents to the nab-paclitaxel/platinum backbone due to its high potency for patients with mTNBC.
科研通智能强力驱动
Strongly Powered by AbleSci AI